Use the hyperlinks, where available to access additional clinical trial information.
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor
This is a randomised trial with an experimental and active comparator arm. Participants in the experimental Arm will receive Imetelstat (9.4mg/kg) intravenously, every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end. Participants in the active comparator arm will receive the best available therapy (BAT), until disease progression or unacceptable toxicity, treatment discontinuation or study end.